Literature DB >> 2532211

Introduction of the alpha subunit mutation associated with the B1 variant of Tay-Sachs disease into the beta subunit produces a beta-hexosaminidase B without catalytic activity.

C A Brown1, K Neote, A Leung, R A Gravel, D J Mahuran.   

Abstract

Lysosomal beta-hexosaminidase (beta-N-acetylhexosaminidase, EC 3.2.1.52) occurs in two major isozyme forms, hexosaminidase A (alpha beta) and hexosaminidase B (beta beta). Although dimer formation is required for enzymatic activity, both subunits contain active sites which share many common substrates. However, the alpha subunit alone confers on hexosaminidase A the specificity for negatively charged substrates, e.g. GM2 ganglioside. Recently, a point mutation, producing a single amino acid substitution in the alpha subunit (Arg178-His), has been found to be associated with the B1 variant phenotype of Tay-Sachs disease (Ohno, K., and Suzuki, K. (1988) J. Neurochem. 50, 316-318). This variant is characterized by normal levels of hexosaminidase A as measured by a common artificial substrate, but an absence of activity toward alpha subunit-specific substrates. However, because of the presence of an active beta subunit in the mutant hexosaminidase A, it has not been possible to determine whether the affected alpha subunit has undergone a change in substrate specificity or become totally inactive. In order to define the full effect of the B1 mutation we have taken advantage of the common evolutionary origin of the genes coding for the alpha and beta subunits. Since the B1 mutation occurs in a region of extended identity between the two subunits, we have duplicated the Arg178-His mutation in a cDNA coding for the human beta subunit (Arg211-His). By expression of the mutant construct in monkey COS cells we have been able to examine the effect of this mutation on beta subunits which are capable of forming stable, active homodimers, an experiment that could not readily be accomplished with heterodimeric hexosaminidase A. Our data show that beta homodimers containing the Arg211-His substitution are formed and are transported into the lysosome in a manner identical to that of normal pro-hexosaminidase B. However, the mutant homodimers are processed at a slower rate and are less stable in the lysozyme. Their most striking feature was a total lack of normal hexosaminidase B activity. We conclude that while the effect of the Arg178-His substitution is not strictly limited to the active site, the severe B1 phenotype results from a totally inactive alpha-subunit in hexosaminidase A.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532211

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Role of beta Arg211 in the active site of human beta-hexosaminidase B.

Authors:  Y Hou; D Vocadlo; S Withers; D Mahuran
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

2.  Cloning and sequence analysis of a cDNA encoding the alpha-subunit of mouse beta-N-acetylhexosaminidase and comparison with the human enzyme.

Authors:  T Beccari; J Hoade; A Orlacchio; J L Stirling
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

3.  A double mutation in exon 6 of the beta-hexosaminidase alpha subunit in a patient with the B1 variant of Tay-Sachs disease.

Authors:  P J Ainsworth; M B Coulter-Mackie
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

4.  Characterization of the Glu and Asp residues in the active site of human beta-hexosaminidase B.

Authors:  Y Hou; D J Vocadlo; A Leung; S G Withers; D Mahuran
Journal:  Biochemistry       Date:  2001-02-20       Impact factor: 3.162

5.  A Cys138-to-Arg substitution in the GM2 activator protein is associated with the AB variant form of GM2 gangliosidosis.

Authors:  B Xie; W Wang; D J Mahuran
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

6.  The Val192Leu mutation in the alpha-subunit of beta-hexosaminidase A is not associated with the B1-variant form of Tay-Sachs disease.

Authors:  Y Hou; G Vavougios; A Hinek; K K Wu; P Hechtman; F Kaplan; D J Mahuran
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 7.  Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on β-hexosaminidase activity in Sandhoff fibroblasts.

Authors:  Elena Chiricozzi; Natalia Niemir; Massimo Aureli; Alessandro Magini; Nicoletta Loberto; Alessandro Prinetti; Rosaria Bassi; Alice Polchi; Carla Emiliani; Catherine Caillaud; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-12-20       Impact factor: 5.590

8.  Introduction of an N-glycan sequon into HEXA enhances human beta-hexosaminidase cellular uptake in a model of Sandhoff disease.

Authors:  Kazuhiko Matsuoka; Daisuke Tsuji; Sei-Ichi Aikawa; Fumiko Matsuzawa; Hitoshi Sakuraba; Kohji Itoh
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

9.  Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.

Authors:  Brian L Mark; Don J Mahuran; Maia M Cherney; Dalian Zhao; Spencer Knapp; Michael N G James
Journal:  J Mol Biol       Date:  2003-04-11       Impact factor: 5.469

10.  beta-Hexosaminidase isozymes from cells cotransfected with alpha and beta cDNA constructs: analysis of the alpha-subunit missense mutation associated with the adult form of Tay-Sachs disease.

Authors:  C A Brown; D J Mahuran
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.